Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors
  • USA - English


News provided by

Research Advisor at Reportbuyer.com

Sep 23, 2013, 11:25 ET

Share this article

Share toX

Share this article

Share toX

London (PRWEB) September 23, 2013 -- Product Description

The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis of the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets:

•Erythropoiesis Stimulating Agents (ESA)
•G-CSF & GM-CSF
•Thrombopoietin & Thrombopoiesis Stimulating Agents
•Interferon
•Insulin
•Coagulation Factors
•Human Growth Hormone (hGH)
•FSH etc
•Thrombolytics & Fibrinolytics
•Enzyme Replacement Therapies

Territories covered are the major pharmaceutical markets North America, Europe and Japan, as well as South Korea, India, China and other countries in Latin America, Africa and Australasia.

With more than US$ 50 bln in sales, therapeutic proteins represent a major category of pharmaceutical products with established therapeutic value and high economic attractiveness. As more and more of the branded products are running out of patent protection and regulatory agencies are providing better guidance, development of biosimilar versions as well as of improved next generation versions are a highly attractive goal for pharmaceutical and biotechnology as well as technology focused companies.

This report includes a compilation of current active projects in research and development of biosimilar and novel biobetter/biosuperior therapeutic proteins as well as non-protein based competitor products and an overview of approved products in regulated and less regulated markets.

Competitor projects are listed in a tabular format providing Information on:

•Drug Codes,
•Target / Mechanism of Action,
•Class of Compound,
•Company,
•Product Category,
•Indication,
•R&D Stage and
•additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Contents

1) Erythropoiesis Stimulating Agents (ESA)

•First generation epoetins in regulated markets
•Second generation epoetins in regulated markets
•Epoetin biosimilars in regulated markets
•Darbepoetin biosimilars in regulated markets
•Next generation biologic Eythropoiesis Stimulating Agents (ESA) in regulated markets
•Next generation small molecule Erythropoiesis Stimulating Agents
•First generation EPO in less regulated markets (Central & South America;
Africa;
Asia;
Rest of the World)
•Darbepoietin biosimilars in less regulated markets
•Next generation biologic Erythropoiesis Stimulating Agents (ESA) in less regulated markets

2) G-CSF and GM-CSF

•2012 Sales of Branded G-CSF Products in Regulated Markets
•1st Generation Branded G-CSF Products in Regulated Markets
•Biosimilar 1st Generation G-CSF Products in Regulated Markets
•Next Generation Branded G-CSF Products in Regulated Markets
•Biosimilar Next Generation G-CSF Products in Regulated Markets
•1st Generation G-CSF Products in Non-Regulated Markets: India
•1st Generation G-CSF Products in Non-Regulated Markets: China & Taiwan
•1st Generation G-CSF Products in Non-Regulated Markets – Korea
•1st Generation G-CSF Products in Non-Regulated Markets – Latin America
•1st Generation G-CSF Products in Non-Regulated Markets: Other Territories
•Next Generation G-CSF Products in Non-Regulated Markets
•1st and Next Generation GM-CSF Products in Regulated Markets
•1st and Next Generation GM-CSF Products in Non-Regulated Markets

3 ) Thrombopoiesis-Stimulating Agents (TPO; IL-11)

•Thrombopoietin receptor (TPO-R) activators
•Interleukin-11 (IL-11) receptor activators
•Small molecule TPO-R Agonists
•Corporate TPO/IL-11 Receptor Agonist Product Portfolios and R&D Pipelines

4 ) Interferon
a) INTERFERON alpha

•Interferon alpha sales 2012 of branded products in regulated markets
•1st generation Interferon alpha-2a in regulated markets
•1st generation Interferon alpha-2a in non-regulated markets
•Next generation Interferon alpha-2a in regulated markets
•Next generation Interferon alpha-2a in non-regulated markets and biosimilars
•1st generation Interferon alpha-2b in regulated markets
•1st generation Interferon alpha-2b in non-regulated markets and biosimilars
•Next generation Interferon alpha-2b in regulated markets
•Next generation Interferon alpha-2b in non-regulated markets and biosimilars
•Other Interferon alpha sub-types
•Interferon alpha with not specified sub-type – 1/2
•Purified natural human interferon alpha

b) Consensus INTERFERONs
c) INTERFERON beta

•Interferon beta sales 2012 of branded products in regulated markets
•1st generation Interferon beta-1a in regulated markets
•1st generation Interferon beta-1a in non-regulated markets and biosimilars
•1st generation Interferon beta-1b in regulated markets
•1st generation Interferon beta-1b in non-regulated markets and biosimilars
•1st generation Interferon beta with not disclosed sub-type
•Next generation Interferon beta in regulated markets
•Purified natural human interferon beta

d) INTERFERON gamma
e) Other INTERFERONs
5 ) Insulin

•2012 Sales of branded recombinant human insulins in regulated markets
•2012 Sales of branded short-acting recombinant human insulin analogs in regulated markets
•2012 Sales of branded long-acting recombinant human insulin analogs in regulated markets
•Rhu insulin (2nd generation) in regulated markets
•Biosimilar rhu insulin (2nd generation) in regulated markets
•Rhu insulin analogs (3rd generation) in regulated markets
•Biosimilar rhu insulin analogs (3rd generation) in regulated markets
•Ultra-long acting rhu insulin formulations and insulin analogs (4th generation)
•Ultra-fast acting rhu insulin formulations and insulin analogs (4th generation)
•Combinations of modern basal and prandial insulin & analogs (4th generation)
•Combinations of insulin & GLP-1 agonist (4th generation)
•Other combinations with insulin
•Oral and Transbuccal Insulins (5th generation)
•Inhaled and transdermal insulin
•Novel approaches for insulin therapy

Rhu insulin (2nd generation) in non-regulated markets: India
•Rhu insulin (2nd generation) in non-regulated markets: China
•Rhu insulin (2nd generation) in non-regulated markets: Other Territories
•Modern insulin analogs (3rd generation) in non-regulated markets
•Animal insulins (1st generation)        

6 ) Coagulation Factors

•Sales of Recombinant Coagulation Factors for Hemophilia in 2012
•Human Plasma-Derived Coagulation Factor VIII Concentrates
•Recombinant Coagulation Factor VIII
•Human Plasma-Derived Coagulation Factor IX
•Recombinant Coagulation Factor IX
•Human Plasma-Derived Factor VII
•Recombinant Coagulation Factor VII
•Human Plasma-Derived Coagulation Factor Concentrates for Willebrand Disease
•Recombinant Human von Willebrand Factor (vWF)
•Human Plasma-Derived Fibrinogen
•Recombinant Human Fibrinogen
•Human Plasma-Derived Factor XI
•Human Plasma-Derived Factor X
•Recombinant Human Factor X
•Human Plasma-Derived Factor XIII
•Recombinant Human Factor XIII
•Alternative Procoagulants & Adjuncts
•Human Plasma-Derived Prothrombin Complex Concentrates
•Gene Therapy of Hemophilia
•Topical Human Plasma-Derived Fibrinogen and Thrombin Products
•Topical Plasma-Derived Thrombin Products
•Topical Recombinant Human Factor II (Prothrombin)
•Alternative Topical Hemostats

7 ) Human Growth Hormone (hGH)

•2012 Sales of Branded Somatropin Products in Regulated Markets
•2012 Sales of Selected Somatropin Products in Non-Regulated Markets
•1st Generation: Somatropin in Regulated Markets

•1st Generation: Biosimilar Somatropin in Regulated Markets
•2nd Generation: Injectable Somatropin in Slow-release Formulation in Regulated Markets
•2nd Generation: Injectable Long-acting Somatropin in Regulated Markets
•2nd Generation: Injection-Free Somatropin in Regulated Markets

•1st Generation: Somatropin Products in Non-Regulated Markets
•2nd Generation: Injectable Long-Acting Somatropin Products in Non-Regulated Markets
•Non-Medical, Legal Uses of Somatropin

8 ) FSH, hCG and LH - Assisted Reproductive Technology (ART)
•Urinary FSH-Containing Products: Menotropins
•Recombinant Menotropins
•1st Generation Purified Human Urinary FSH
•2nd Generation Recombinant Human FSH
•Biosimilar Recombinant Human FSH
•2nd Generation Rhu FSH in Non-Regulated Markets
•3rd Generation Rhu FSH
•Purified Urinary Human Choriogonadotropin (hCG)
•Recombinant Human Choriogonadotropin (rhCG)
•Recombinant Human Luteinizing Hormone (rhLH)
•hCG Receptor Agonist

9 ) Thrombolytics & Fibrinolytics

•Non-fibrin selective (1st generation) Fibrinolytics
•Fibrin selective wild-type t-PA-based Fibrinolytics
•Fibrin selective engineered t-PA-based Fibrinolytics
•Non-t-PA-based Fibrinolytics
•Plasmin-based Fibrinolytics
•Adjunctive therapy to Fibrinolytics
•Biosimilar Thrombolytics and Fibrinolytics in Non-Regulated Markets
•Corporate Thrombolytic Product Portfolios and R&D Pipelines

10) Enzyme Replacement Therapies

•Gaucher Disease
•Fabry Disease
•Pompé Disease
•Hunter Disease (MPS II)
•Niemann Pick Diseases
•Mucopolysaccharidosis I (MPS I)
•San Filippo Syndrome (MPS IIIA)
•Morquio Syndrome (MPS IVA)
•Mucopolysaccharidosis VI (MPS VI)
•Tay-Sachs Disease
•Chronic Deficiency of Adenosine Deaminase
•Phenylketonuria / Hyperphenylalaninemia
•Other Enzyme Replacement Therapies
•Exocrine Pancreatic Insufficiency: Porcine-Derived ERT
•Exocrine Pancreatic Insufficiency: Recombinant ERT
•Others
Read the full report:

Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors

http://www.reportbuyer.com/countries/asia_pacific/south_korea/competitor_analysis_therapeutic_proteins_biosimilars_biobetters_biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical
For more information:

Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com

Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.